ID   Karpas-25
AC   CVCL_2540
SY   KARPAS-25; Karpas 25; KARPAS 25; Karpas25
DR   ECACC; 06072601
DR   Wikidata; Q54899494
DR   Ximbio; 152420
RX   CelloPub=CLPUB00604;
RX   PubMed=10936422;
RX   PubMed=15621787;
RX   PubMed=32123307;
WW   https://www.keatslab.org/myeloma-cell-lines/hmcl-characteristics
CC   Doubling time: ~30 hours (ECACC=06072601; Ximbio=152420).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   27Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 15
//
RX   CelloPub=CLPUB00604;
RA   Chow S.;
RT   "Targeted capture and sequencing of immunoglobulin rearrangements
RT   in multiple myeloma to enable detection of minimal residual disease.";
RL   Thesis MSc (2017), University of Toronto, Canada.
//
RX   PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   multiple myeloma and plasma cell leukemia.";
RL   Leuk. Res. 24:681-703(2000).
//
RX   PubMed=15621787; DOI=10.1080/10428190400002244;
RA   Karpas A., Harder L., Czepulkowski B.H., Bloxham D., Saward R.,
RA   Dremucheva A., Siebert R.;
RT   "Studies of four new human myeloma cell lines.";
RL   Leuk. Lymphoma 46:101-112(2005).
//
RX   PubMed=32123307; DOI=10.1038/s41375-020-0785-1;
RA   Sarin V., Yu K., Ferguson I.D., Gugliemini O., Nix M.A., Hann B.,
RA   Sirota M., Wiita A.P.;
RT   "Evaluating the efficacy of multiple myeloma cell lines as models for
RT   patient tumors via transcriptomic correlation analysis.";
RL   Leukemia 34:2754-2765(2020).
//